PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New targets for CAR-T cell therapy against acute myeloid leukemia through AI-assisted analysis

Interdisciplinary cooperation between LMU and Helmholtz Munich supported by Bavarian Research Foundation

2023-03-13
(Press-News.org) Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy. The reason is that specific molecular targets with which certain immune cells could specifically target AML cells are lacking, which would permit the immune system to attack cancer. Two research teams of Professor Dr. Sebastian Kobold with Dr. Adrian Gottschlich from the Division of Clinical Pharmacology at LMU University Hospital Munich and Dr. Carsten Marr with Moritz Thomas from the Institute of AI for Health at Helmholtz Munich have now succeeded in discovering such targets. The results have now been published in the journal Nature Biotechnology.

AML – one of several forms of leukemia (“blood cancer”) – is a treacherous disease. Five years after the initial diagnosis, only one-third of patients are still alive. Up to 85 percent of patients appear to be cured after intensive chemotherapy. However, in more than half of them, the disease returns within one to two years because the chemotherapy has not destroyed all leukemia cells. In the event of a relapse, a stem cell transplant is the only hope for cure for a patient. But even then, the long-term probability of survival is less than 20 percent. New treatment options are therefore urgently needed.

CAR-T cell therapy is an innovative therapy. CAR-T stands for “chimeric antigen receptor in T cells”. T cells are cells of the immune system. Cancer cells evade their “normal” attempts to attack them by using various molecular tricks. Thus, T cells no longer recognize their opponents, the cancer cells. During CAR-T cell therapy, T cells are first removed from the patients and then genetically engineered to produce a specific protein (CAR) on their surface. When these CAR-T cells are injected back into the patient’s body, these will only engage their target: CD19, which ensures that they recognize the patient’s cancer cells and bind to them in a targeted manner. The cancer cells consequently die.

New targets

However, the approved CAR-T cells against CD19 are not suitable for AML, because CD19 is (usually) not present on the surface of AML cells. Clinical results with CAR-T cells directed against other surface molecules of AML cells have been sobering so far, according to scientists. This is because CAR-T cells were unable to distinguish between healthy and degenerated cells – with correspondingly induced significant side effects.

The physician Sebastian Kobold and the physicist Carsten Marr, together with colleagues from the LMU University Hospital Munich and the Institute of AI for Health at Helmholtz Munich, set out to find alternative molecules that would ideally be found exclusively on the surface of AML cells. With the help of extensive bioinformatic analyses and the integration of expression data from more than half a million individual cells, two candidates finally crystallized out of 25,000 potential cell surface molecules. These are known as CSF1R and CD86. “Such an analysis would not have been possible a few years ago, since the required single-cell data has been generated only very recently,” says Marr, who led the AI-assisted analysis in the study at Helmholtz Munich.

The researchers produced CAR-T cells in the laboratory of the LMU University Hospital Munich that precisely target these molecules. The cells were then tested on different AML models, including AML cells from patients. The results, according to Kobold are promising: “On the one hand, these CAR-T cells are effective against AML, but on the other hand, they hardly destroy healthy cells.”

The study impressively demonstrates how the synergy of interdisciplinary research groups can lead to breakthroughs in health research to treat patients in the best possible way. The researchers’ next goal: They want to develop GMP (good manufacturing practice)-capable processes to produce CAR-T cells that can then also be used in clinical trials with AML patients. This is to take place within the framework of the “Bavarian Cell Therapy Catalyst”, which is supported by the Bavarian Research Foundation. Kobold expects the first tests with patients in two to three years.

END


ELSE PRESS RELEASES FROM THIS DATE:

The fat tax: Long-term, systemic antibiotic use for the treatment of adolescent acne can promote fat accumulation

The fat tax: Long-term, systemic antibiotic use for the treatment of adolescent acne can promote fat accumulation
2023-03-13
A growing body of evidence is showing that the healthy gut microbiome – a community of microorganisms that live together in the gut – influences many aspects of human growth and development, especially during adolescence. While there are many physiologic changes during this time, one of the most outward facing, and sometimes distressing, is the development of acne. Most individuals treat their acne with topical therapies; however, around 25% of adolescents require systemic antibiotics, such as minocycline, to help to alleviate symptoms and clear up the skin. These systemic antibiotic ...

Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform

Insilico Medicine brings AI-powered “ChatPandaGPT”  to its target discovery platform
2023-03-13
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, “ChatPandaGPT,” enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner. Insilico Medicine is the first biotech company to implement chat functionality using large language models into its AI drug ...

Oncotarget | Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells

Oncotarget | Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
2023-03-13
“Selective protection of normal cells may transform therapy of cancer.”  BUFFALO, NY- March 13, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.” Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center discusses the theory that cancer resistance to certain therapies can be exploited ...

Agriculture needs fresh approach to tackle insect resistance to biopesticides, new analysis finds

Agriculture needs fresh approach to tackle insect resistance to biopesticides, new analysis finds
2023-03-13
Insect pests which attack crops have extraordinary powers to develop resistance to greener pesticides and a new way to manage resistance risks is needed, according to analysis by University of Stirling scientists. For more than 70 years, agriculture’s response to pesticide resistance has been to seek new pesticides in an endless race to keep up with evolving pests. Researchers now propose a new way to step off this treadmill as farmers embrace the ongoing green revolution in pest control by switching to biopesticides derived from natural organisms. The evolution of resistance to biopesticides - a crucial tool in ...

Racial health inequality in prostate cancer associated with facility-level disparities

2023-03-13
Racial minorities in the United States are less likely to receive treatment for prostate cancer and, overall, have worse survival outcomes compared to individuals who are white. Typically, patient-level and physician-level factors have been used to explain the racial and socioeconomic differences in prostate cancer disparities. However, a new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, investigated the role of facilities themselves ...

Scientists develop new concepts about the shape and dynamic nature of molecules

2023-03-13
-With pictures- Scientists have demonstrated in a new study that carbon-based molecules can be much more dynamic than previously thought. When a carbon atom forms four bonds to different groups, the molecule can exist in two mirror image forms. These mirror image forms are vital in medicine because they have different biological activities. Usually, it is impossible to interconvert between these ‘enantiomers’ because to do so would require a bond to be broken, a process that needs too much energy. The researchers ...

Minke whales are as small as a lunge-feeding baleen whale can be

Minke whales are as small as a lunge-feeding baleen whale can be
2023-03-13
A new study of Antarctic minke whales reveals a minimum size limit for whales employing the highly efficient “lunge-feeding” strategy that enabled the blue whale to become the largest animal on Earth. Lunge feeding whales accelerate toward a patch of prey, engulf a huge volume of water, and then filter out the prey through the baleen plates in their mouths. This strategy is used by the largest group of baleen whales, known as rorquals, which includes blue, fin, humpback, and minke whales. The ability ...

UK scientists discover a new way to help prevent breast cancer ‘time bomb’

2023-03-13
Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep - forming incurable secondary tumours. Their research, funded by Breast Cancer Now, reveals the mechanism that triggers this breast cancer 'time bomb' – and suggests a strategy to defuse it. Patients with oestrogen receptor positive (ER+) breast cancer – the most common type – have a continued risk of their cancer recurring in another part of their body for many years or even decades after their original ...

The right cocktail of gut enzymes can stop c. diff in its tracks

2023-03-13
Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment. The work could lead to “designer” probiotics that protect against disease by introducing specific BSHs to the gut after antibiotic treatment. Selecting the right suite of BSH-producing bacteria is critical, because the study found that interactions between BSHs and bile acids ...

Researchers identify novel genes that may increase risk for schizophrenia

2023-03-13
New York, NY (March 13, 2023) – Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism. Led by the Icahn School of Medicine at Mount Sinai, the multi-center study further demonstrated that the schizophrenia risk conferred by these rare damaging variants is conserved across ethnicities. The study may also point to new therapeutics. The findings were published in the March 13 online issue of Nature ...

LAST 30 PRESS RELEASES:

Editorial urges deeper focus on heart-lung interactions in pulmonary vascular disease

Five University of Tennessee faculty receive Fulbright Awards

5 advances to protect water sources, availability

OU Scholar awarded Fulbright for Soviet cinema research

Brain might become target of new type 1 diabetes treatments

‘Shore Wars:’ New research aims to resolve coastal conflict between oysters and mangroves, aiding restoration efforts

Why do symptoms linger in some people after an infection? A conversation on post-acute infection syndromes

Study reveals hidden drivers of asthma flare-ups in children

Physicists decode mysterious membrane behavior

New insights about brain receptor may pave way for next-gen mental health drugs

Melanoma ‘sat-nav’ discovery could help curb metastasis

When immune commanders misfire: new insights into rheumatoid arthritis inflammation

SFU researchers develop a new tool that brings blender-like lighting control to any photograph

Pups in tow, Yellowstone-area wolves trek long distances to stay near prey

AI breakthrough unlocks 'new' materials to replace lithium-ion batteries

Making molecules make sense: A regional explanation method reveals structure–property relationships

Partisan hostility, not just policy, drives U.S. protests

The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 1, 2025

Young human blood serum factors show potential to rejuvenate skin through bone marrow

Large language models reshape the future of task planning

Narrower coverage of MS drugs tied to higher relapse risk

Researchers harness AI-powered protein design to enhance T-cell based immunotherapies

Smartphone engagement during school hours among US youths

Online reviews of health care facilities

MS may begin far earlier than previously thought

New AI tool learns to read medical images with far less data

Announcing XPRIZE Healthspan as Tier 5 Sponsor of ARDD 2025

Announcing Immortal Dragons as Tier 4 Sponsor of ARDD 2025

Reporting guideline for chatbot health advice studies

Announcing Mitra Bio as Tier 3 Sponsor of ARDD 2025

[Press-News.org] New targets for CAR-T cell therapy against acute myeloid leukemia through AI-assisted analysis
Interdisciplinary cooperation between LMU and Helmholtz Munich supported by Bavarian Research Foundation